{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "GI Signals - Motility",
  "home_page_url": "https://siftingsignal.com/gisignals/",
  "feed_url": "https://siftingsignal.com/gisignals/feed/motility.json",
  "description": "Motility papers worth knowing in GI this week. A SiftingSignal publication.",
  "items": [
    {
      "id": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42387275",
      "url": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42387275",
      "title": "Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.",
      "date_published": "2026-07-09T16:47:07Z",
      "content_text": "Alimentary pharmacology & therapeutics. Where it is available (Japan, India, not the US), a single non-randomized study suggests elobixibat may outperform prucalopride on sustained CSBM in refractory functional constipation, but this is hypothesis-generating and does not change guideline-based US practice, where elobixibat is unavailable."
    },
    {
      "id": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42392123",
      "url": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42392123",
      "title": "The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study.",
      "date_published": "2026-07-09T16:47:07Z",
      "content_text": "The lancet. Gastroenterology & hepatology. Rome V criteria show lower sensitivity (66.1%) compared to Rome IV (78.9%) and Rome III (87.5%) in this secondary care study. No clinical action yet; await further validation and SOC updates."
    },
    {
      "id": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413530",
      "url": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413530",
      "title": "Barrier restoration as a therapeutic strategy for disorders of gut-brain interaction.",
      "date_published": "2026-07-09T16:47:07Z",
      "content_text": "The lancet. Gastroenterology & hepatology. This mechanistic review of gut-barrier restoration (SCFAs, glutamine or tryptophan, probiotics) is hypothesis-generating only; barrier-targeted diet or probiotic therapy for disorders of gut-brain interaction is not yet guideline-supported and should await clinical trials."
    },
    {
      "id": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413705",
      "url": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413705",
      "title": "Acupuncture versus sham non-acupoint acupuncture for irritable bowel syndrome: a systematic review and meta-analysis.",
      "date_published": "2026-07-09T16:47:07Z",
      "content_text": "Gastroenterology. Acupuncture may improve IBS symptoms compared to sham, but the high heterogeneity and low certainty of evidence limit clinical applicability. Discuss these limitations if patients inquire about acupuncture."
    }
  ]
}